NASDAQ$AGIO
Agios Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Agios reported second quarter 2024 financial results and business highlights.
Agios Pharmaceuticals reported PYRUKYND® net revenue of $8.6 million in Q2 2024 and announced a $905 million purchase agreement for vorasidenib royalty with Royalty Pharma. The company's cash, cash equivalents and marketable securities totaled $645.3 million as of June 30, 2024. They also reported positive topline data from Phase 3 ENERGIZE-T Study and expect to file sNDA based on ENERGIZE and ENERGIZE-T Studies by the end of 2024.
- PYRUKYND® net revenue reached $8.6 million, a 5% sequential increase from Q1 2024.
- A total of 201 unique patients have completed prescription enrollment forms for PYRUKYND®, representing a 7% increase over the first quarter of 2024.
- Agios announced a $905 million purchase agreement with Royalty Pharma for vorasidenib royalty.
- Topline data was reported in the Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency.
Headline financials
Revenue & EPS history
Agios · Revenue · Quarterly
$8.62M
Forward guidance
Agios expects to execute on key milestones and priorities by the end of 2024.
Tailwinds
- File sNDA for mitapivat in thalassemia based on the positive results from the Phase 3 ENERGIZE and ENERGIZE-T trials (year-end).
- Complete enrollment in the Phase 3 portion of the RISE UP study of mitapivat (year-end).
- Dose first patient in Phase 2b study of tebapivat (AG-946) (mid-year).
- Potential approval of Servier’s vorasidenib for the treatment of IDH-mutant diffuse glioma.
- The FDA has assigned a PDUFA action date of August 20, 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.0%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.9%
Avg return
30 days after
50%
25 / 50 earnings
Positive
+19.2%
Q2 2022
Best reaction
-15.0%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.1% | +18.5% | |
| Q4 2025 | +1.3% | +0.4% | +0.5% | |
| Q3 2025 | +2.8% | -4.7% | -30.4% | |
| Q1 2025 | +4.2% | -4.6% | +8.1% | |
| Q4 2024 | +1.5% | +2.4% | -5.7% | |
| Q3 2024 | -3.1% | +0.9% | +28.3% | |
| Q2 2024 | -5.3% | -8.2% | -1.1% | |
| Q1 2024 | +2.6% | -2.6% | +8.0% | |
| Q4 2023 | +2.4% | +4.6% | +15.6% | |
| Q3 2023 | +5.6% | +9.1% | +7.5% | |
| Q2 2023 | -2.0% | +0.1% | +8.4% | |
| Q1 2023 | +11.7% | +11.1% | +13.9% | |
| Q4 2022 | -5.3% | -4.6% | -18.0% | |
| Q3 2022 | -6.9% | -2.0% | +13.3% | |
| Q2 2022 | +19.2% | +9.7% | +27.7% | |
| Q1 2022 | -6.3% | -9.7% | -18.5% | |
| Q4 2021 | +11.8% | +16.9% | +4.5% | |
| Q3 2021 | -7.3% | -9.1% | -31.3% | |
| Q2 2021 | -3.8% | -5.8% | -9.9% | |
| Q1 2021 | +0.7% | -3.4% | +0.6% | |
| Q4 2020 | -10.3% | -7.5% | -6.1% | |
| Q3 2020 | -5.5% | +0.2% | +7.7% | |
| Q2 2020 | -8.3% | -10.7% | -18.9% | |
| Q1 2020 | -15.0% | -9.4% | +18.8% | |
| Q4 2019 | +4.3% | +7.9% | -24.9% | |
| Q3 2019 | +6.4% | +9.2% | +23.0% | |
| Q2 2019 | -12.6% | -15.5% | -21.1% | |
| Q1 2019 | +3.2% | -5.1% | -13.2% | |
| Q4 2018 | +9.7% | +6.8% | +20.3% | |
| Q3 2018 | +11.6% | +13.1% | +4.3% | |
| Q2 2018 | -9.0% | -7.3% | -6.9% | |
| Q1 2018 | -0.9% | +1.1% | +17.5% | |
| Q4 2017 | +3.0% | +1.5% | +8.4% | |
| Q3 2017 | +0.0% | +3.6% | -4.8% | |
| Q2 2017 | -0.8% | -3.6% | +4.5% | |
| Q1 2017 | +6.8% | +7.5% | +5.1% | |
| Q4 2016 | +17.3% | +9.3% | +16.3% | |
| Q3 2016 | +7.3% | +17.2% | +23.6% | |
| Q2 2016 | -6.3% | -11.0% | -21.0% | |
| Q1 2016 | -7.2% | — | — | |
| Q4 2015 | -8.3% | — | — | |
| Q3 2015 | -2.6% | — | — | |
| Q2 2015 | -12.4% | — | — | |
| Q1 2015 | +13.3% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | -10.3% | — | — | |
| Q3 2013 | +3.2% | — | — | |
| Q2 2013 | +6.4% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro